Table 1.
Characteristics of the study population.
| Characteristics | N | |
|---|---|---|
| Age (year)a | 49.79 ± 13.53 | 109 |
| History (year)b | 3.00 (0.00–8.00) | 109 |
| Male n (%)c | 55.05 | 60 |
| BMI (kg/m2)a | 24.99 ± 3.30 | 109 |
| SBp (mmHg)a | 125.76 ± 14.97 | 109 |
| DBp (mmol/L)a | 80.76 ± 9.45 | 109 |
| FINS (pmol/L)b | 114.55 (70.78–156.52) | 109 |
| FBG (mmol/L)a | 8.15 ± 3.28 | 109 |
| HOMA-IRa | 5.68 ± 2.05 | 109 |
| Fasting peptide C (μIU/mL)a | 2.05 ± 1.01 | 109 |
| 25(OH)D (ng/mL)a | 21.10 ± 10.39 | 109 |
| Vitamin D deficiency [n (%)]c | 54.13 | 59 |
| Vitamin D insufficiency [n (%)]c | 24.77 | 27 |
| Vitamin D sufficiency [n (%)]c | 21.10 | 23 |
| HbA1c (%)a | 9.49 ± 2.79 | 109 |
| TG (mmol/L)b | 1.65 (1.06–2.63) | 109 |
| TC (mmol/L)a | 5.15 ± 1.13 | 109 |
| HDL-C (mmol/L)b | 1.23 (1.10–1.45) | 109 |
| LDL-C (mmol/L)a | 3.08 ± 1.02 | 109 |
| Apo-A1 (g/L)b | 1.37 (1.18–1.74) | 109 |
| Apo-B (g/L)a | 1.03 ± 0.32 | 109 |
| Bun (mmol/L)b | 4.80 (4.15–5.64) | 109 |
| Cr (μmol/L)b | 56.50 (48.23–69.68) | 109 |
| eGFR (mL/min)b | 111.70 (93.85–130.25) | 109 |
| Ca (mmol/L)a | 2.33 ± 0.13 | 109 |
| P (mmol/L)a | 1.36 ± 0.15 | 109 |
| Calcium [(mg/dL)2]a | 39.24 ± 5.11 | 109 |
| iPTH (pg/mL)a | 43.05 ± 14.27 | 109 |
| BALP (u/L)a | 184.72 ± 14.77 | 109 |
| IGF-1 (pg/mL)a | 276.65 ± 146.52 | 109 |
| Cys (mg/L)b | 0.98 (0.91–1.14) | 109 |
| Hcy (μmol/L)a | 9.10 ± 4.11 | 109 |
a
Mean ± SD.
b
Median (interquartile range).
c
Percentage.
HOMA-IR, homeostatic model estimates of insulin resistance; 25(OH)D, 25-hydroxy vitamin D; TC, total cholesterol; LDL, low-density lipoprotein; Ca, serum calcium; P, serum phosphorus; eGFR, glomerular filtration rate; FINS, fasting blood insulin; TG, triglyceride; HDL, high-density lipoprotein; BUN, blood urea nitrogen; SCr, serum creatinine; HbA1c, glycated hemoglobin A1c; iPTH, intact parathyroid hormone.